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Volume 60, Number 3 Abstracts 817OPG cohort were stratiﬁed into low-risk and high-risk groups based on age,
distal target, poor conduit quality, and procedures performed for tissue loss.
However, in the era of endovascular revascularization, few patients who un-
dergo LEB fall into the low-risk OPG category. Therefore, the goal of this
study was to determine safety and efﬁcacy measures for those patients who
do not fall into the OPG cohort.
Methods: All patients who underwent LEB for CLI in the Vascular
Study Group of New England database from 2003 to 2013 were identiﬁed.
Patients were stratiﬁed by OPG criteria into OPG and non-OPG cohorts,
and the OPG cohort was divided into high-risk and low-risk strata. Out-
comes included 30-day major adverse limb event, 30-day major adverse car-
diac event (MACE), 1-year survival, 1-year limb salvage, and 1-year primary
patency rates.
Results: We identiﬁed 4190 patients: 2649 (63%) OPG and 1541
(37%) non-OPG. Of the OPG cohort, 2506 (95%) were high risk, 143
(5%) were low risk. A total of 1467 (35%) had a previous bypass (43%
non-OPG, 30% OPG; P < .001). The 30-day major adverse limb event
was 5.6% (6% non-OPG, 5.4% OPG; P ¼ .36), and the MACE was 8.3%
(10.3% non-OPG, 7.1% OPG; P < .001). At 1 year, limb salvage was
85% (77% non-OPG, 89% OPG; P < .001), survival was 83% (75% non-
OPG, 87% OPG; P < .001), and primary patency was 70% (72% OPG,
66% non-OPG; P ¼ .009).
Conclusions: In contemporary practice, 97% of patients undergo-
ing LEB for CLI would be excluded or considered high risk based on
the Society for Vascular Surgery OPG criteria and therefore cannot be
held to this standard. For the non-OPG group, the 30-day MACE of
10.3%, 1-year limb salvage of 77%, and 1-year survival of 75% are lower
than OPG metrics but are more realistic in this high-risk cohort of
patients.
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Objectives: We evaluated the safety and effectiveness of the Zenith
TX2 Low Proﬁle Endovascular Graft for the treatment of descending
thoracic aortic aneurysms and large ulcers.
Methods: The Zenith TX2 Low Proﬁle Endovascular Graft, with a
16F to 20F delivery system, was developed to address vascular access is-
sues associated with larger-proﬁle devices and to increase conformability
in tortuous anatomy. This prospective, nonrandomized, multicenter
study was conducted in Europe, Japan, and the United States. Main
anatomical inclusion criteria included proximal neck of $20 mm, aortic
arch radius of $20 mm, and a neck diameter of 15 to 42 mm. Patients
were evaluated preprocedure, predischarge, at 1, 6, and 12 months, and
yearly thereafter through 5 years. One-year results as of December 2,
2013, are presented.
Results: Between March 2010 and January 2013, 110 patients
(mean age, 72 6 10 years) were treated with the TX2 Low Proﬁle device
for descending thoracic aortic aneurysms (n ¼ 90) or ulcers (n ¼ 20).
Women constituted 42% (46 of 110) of the study population. Percuta-
neous access was performed in 31% (34 of 110). The study device was
successfully implanted in all but two patients (both failure of delivery
due to severe iliac calciﬁcation). There was no 30-day mortality. Three
deaths occurred #1 year; none were judged aneurysm-related or
repair-related by independent adjudication. One-year morbidity included
stroke in ﬁve patients (2 procedure-related by independent adjudication)
and renal failure in two patients (both with a preoperative history of
chronic kidney disease). Secondary endovascular intervention was per-
formed in two patients, one for type II endoleak and one for proximal
dissection. No conversions, rupture, Q-wave myocardial infarction, or
paraplegia was observed #1 year.
Conclusions: Early outcomes appear promising and suggest
expanded thoracic endovascular aortic repair applicability with increased fe-
male population and percutaneous access. Longer-term follow-up is
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Objectives: Use of ﬂuoroscopy and bony landmarks to guide percuta-
neous common femoral artery (CFA) access has decreased access site com-
plications compared with palpation alone. However, only limited case series
have examined the beneﬁts of ultrasound imaging to guide CFA access dur-
ing peripheral vascular intervention (PVI). We evaluated the effect of
routine vs selective use of UG on groin hematoma rates after PVI.
Methods: The Vascular Study Group of New England database
(2010-2014) was queried to identify the complication of postprocedural
groin hematoma after 7359 PVIs performed by CFA access. Hematoma
(including pseudoaneurysms) was deﬁned as minor (requiring compression
or observation), moderate (requiring transfusion or thrombin injection),
and major (requiring operation). Multivariable Poisson regression models
were used to compare hematoma rates of surgeons based on routine
($80% PVI) and selective (<80%) use of UG in the adjusted overall sample
and in multiple subgroups.
Results: The overall groin hematoma rate after PVI was 4.5%, and the
rate of combined moderate and major hematoma was 0.8%. Among 114
surgeons with $10 PVI procedures, 31 surgeons (27%) used UG routinely
and 83 (73%) used UG selectively. Routine UG was protective against he-
matoma (rate ratio [RR], 0.74; 95% conﬁdence interval [CI], 0.57-0.95; P
¼ .02). Subgroup analysis revealed that routine UG was also protective
against hematoma under the following circumstances: age >80 years (RR,
0.47; 95% CI, 0.26-0.85; P ¼ .01), body mass index $30 kg/m2 (RR,
0.51; 95% CI, 0.29-0.90; P ¼ .02), timing of procedure in the ﬁrst half
of the academic year (RR, 0.56; 95% CI, 0.38-0.82; P < .01), and sheath
size >6F (RR, 0.43; 95% CI, 0.23-0.79; P < .01).
Conclusions: Routine UG may potentially protect against the
complication of hematoma for modiﬁable and nonmodiﬁable patient/pro-
cedural characteristics. Encouraging routine UG is a feasible quality
improvement opportunity to decrease patient morbidity after PVI.
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Objectives: T cells regulate adaptive immunity and a number of forms
of vascular remodeling, but their role in venous thrombus resolution re-
mains undeﬁned. Our objective was to deﬁne the presence and function
of T cells during resolution of deep venous thrombosis in vivo.
Methods: Thrombus resolution was studied in CD-1 mice after
inducing stasis deep venous thrombosis by vena caval ligation. Inﬂammatory
cell subtypes were characterized by immunohistochemistry and ﬂow cytom-
etry of thrombi at various time points. The role of T cells in mediating
thrombus resolution was deﬁned by T-cell depletion with anti-CD-3 or con-
trol antibody treatment and by thrombus resolution assessed by thrombus +
vein wall weight at day 12. Gene expression after T cell depletion was stud-
ied by Western blotting and zymography of thrombi.
Results: Immunocytochemistry of thrombus and vein wall sections
did not consistently demonstrate the presence of T cells during
thrombus resolution (days 2 to 12) but did show typical patterns of
neutrophil and then macrophage inﬁltration. Flow cytometry of cell sus-
pensions from thrombi identiﬁed 2.93% of cells as CD3+ T cells at day 8,
with a peak of 48% CD3+ T cells and 10% B cells at day 8. Immunosub-
typing revealed regulatory CD4 T cells (40%) and cytotoxic CD8 T cells
(30%) on day 8. T-cell depletion with anti-CD3 antibody treatment dur-
ing thrombus resolution (days 0 to 12) reduced spleen T-cell counts byyNew England Society for Vascular Surgery
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